Value Sense
HALO
Halozyme Therapeutics, Inc. (HALO)
Last Price$61.4(0.0%)
Market Cap$7,773.1M
WACC
8.7%
Cost of Equity
10.4%
Cost of Debt
0.2%
Debt to Equity
19.4%
Beta
0.8
Stock quality
8/10
Great
HALO
is 10.3% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

HALO WACC

Recent WACC calculation

as of Mar 11, 2025
Cost of Equity
% share of Total Capital
10.4%
83.8%
Risk-free rate
4.3%
Beta
1.3
Equity Risk Premium
4.6%
Country risk premium
0.0%
Cost of Debt (after-tax)
% share of Total Capital
0.2%
16.2%
Average Cost of Debt
0.3%
Effective Tax Rate
23.1%
WACC
8.7%

WACC dynamics

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

HALO Cost of Equity

Recent Cost of Equity calculation

as of Mar 11, 2025
Risk-free rate
4.3%
Beta
1.3
Equity risk premium
4.6%
Country risk premium
0.0%
Cost of Equity
10.4%

Cost of Equity dynamics

HALO vs Peer Set: Discount Rate Comparison

WACC
Cost of Equity

General

Discount rate

financials

Company name

Revenue growth

EPS growth

Net Income margin

Halozyme Therapeutics, Inc. logo
Halozyme Therapeutics, Inc.HALO
8.7%
22.4%
64.3%
43.7%
Median Peer Set
7.3%
14.8%
(19.3%)
7.5%
Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
7.5%
N/A
(68.7%)
N/A
BioNTech SE logo
BioNTech SEBNTX
7.4%
(77.4%)
(89.7%)
24.4%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
7.4%
11.7%
N/A
(4.9%)
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
7.4%
23.6%
25.7%
41.5%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
7.3%
8.3%
10.4%
31.1%
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
7.2%
23.0%
(38.6%)
(12.4%)
BioMarin Pharmaceutical Inc. logo
BioMarin Pharmaceutical Inc.BMRN
7.2%
18.0%
139.3%
15.0%
Royalty Pharma plc logo
Royalty Pharma plcRPRX
5.1%
(3.8%)
(43.7%)
37.9%
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
4.9%
73.7%
467.1%
(35.9%)
argenx SE logo
argenx SEARGX
negative
198.6%
(60.5%)
(24.1%)

Explore more intrinsic value tools hub for HALO

Peter Lynch Fair Value
Margin of safety
Reverse DCF
Relative Value
DCF value calculator
Ben Graham Fair Value
Intrinsic Value
Peter Lynch charts
Earnings growth model
Earnings Power Value

FAQ

What is Halozyme Therapeutics, Inc.'s discount rate as of Mar 11, 2025?

As of Mar 11, 2025, Halozyme Therapeutics, Inc.'s discount rate is 8.72%. This rate is determined based on the weighted average cost of capital (WACC) and the cost of equity, factoring in Halozyme Therapeutics, Inc.'s capital structure and risk profile.

What is Halozyme Therapeutics, Inc.'s weighted average cost of capital (WACC)?

Halozyme Therapeutics, Inc.'s WACC as of Mar 11, 2025, is 8.72%. This value is calculated by blending the cost of debt and cost of equity, reflecting the company’s overall cost of financing its operations.

What is Halozyme Therapeutics, Inc.'s cost of equity?

Halozyme Therapeutics, Inc.'s cost of equity is 10.4%, as of Mar 11, 2025. This is the return that shareholders expect based on the stock's risk level and market conditions, used to calculate the discount rate for valuing future cash flows.